Takeda Says Last Pre-Shire Quarter ‘Robust’, But Quiet On Divestments

Takeda saw continued growth for mainstay drugs in what it described as a ‘robust’ last quarter of reporting before the inclusion of Shire, with global blockbuster Entyvio leading the way, but gave away little new on widely anticipated post-deal divestments.

Takeda
Takeda Logs Growth In Last Pre-Shire Quarter • Source: Shutterstock

Takeda Pharmaceutical Co. Ltd. has logged a generally solid last quarter of results before the impact of its acquisition of Shire PLC begins to kick in, with mainstay products growing globally and the results of ongoing cost savings driving margin improvement.

While again committing to the general principle of non-core asset sales to pay down debt associated with the acquisition, formally...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Japan

More from Focus On Asia